This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Renishaw Diagnostics expands Glasgow operation

09 September 2010

Renishaw Diagnostics, a specialist provider of trace level detection technologies based on the exploitation of Surface Enhanced Raman Spectroscopy (SERS) and Surface Enhanced Resonance Raman Scattering (SERRS) for clinical research and molecular diagnostics applications, has officially opened its expanded premises on the Nova Technology Park, Glasgow, Scotland.
The company (previously known as D3 Technologies) first moved into the custom-built laboratory and office space on the technology park in December 2007. The successful outcome required expanded facilities for an increased number of research and commercial staff.

The Opening Ceremony was performed by Sir David McMurtry (pictured centre in this photograph), Renishaw’s chairman and Chief executive, and attended by Renishaw staff from across the UK as well as representatives from Scottish Enterprise, Scottish Development International, the Scottish Parliament and Nexxus, central Scotland’s life sciences network.

Renishaw Diagnostic’s chief executive, David Burns (left), said, “I am delighted to welcome so many people to our new premises to see the facilities and to meet our highly skilled and dedicated staff. Renishaw Diagnostics will launch its first products into the molecular diagnostics market next year and we plan to become a major supplier of multiplexed molecular diagnostic systems for infectious diseases. This will allow clinicians to diagnose and treat more quickly.”

Lena Wilson (right), chief executive of Scottish Enterprise, said, "Renishaw Diagnostics is already showing huge promise in the field of molecular diagnostics and its expansion at Nova Technology Park is another big boost for Scotland’s world-leading life sciences industry. “RSA funding is one of the key tools we can use to encourage both indigenous and foreign companies to invest in Scotland and we are thrilled that this funding has enabled Renishaw to invest in its Scottish base and create new jobs for Scotland.

“Renishaw Diagnostics is exactly the type of ambitious, growing and sustainable enterprise that Scotland needs more of, and we look forward to working closely with the team to help them realise their ambitious plans for growth.”
 


Contact Details and Archive...

Print this page | E-mail this page

Drives and Controls 2020